olaratumab
Trade name: lartruvo
mAbapprovedOrphan Drug FDAFast Track FDABreakthrough Therapy FDA
Approved
Oct 19, 2016
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. — Wikipedia
Clinical trial activity
23 trials · 12 clinical orgs · 1 marketing orgs
Phase 1
14
Phase 2
12
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00768391)
Timeline
2000s
Indications
Approved for
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Fibrosarcoma · Phase 2
- Glioblastoma · Phase 2
- Hemangiosarcoma · Phase 2
- Intestinal Neoplasms · Phase 2
- Leiomyosarcoma · Phase 2
- Liposarcoma · Phase 2
- Neoplasm Metastasis · Phase 1
- Neurofibrosarcoma · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 2
- Sarcoma, Synovial · Phase 2
Mechanism of action
PDGFRA antagonist
Human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that binds to PDGFRalpha and blocks the PDGF-AA, PDGF-BB, and PDGF-CC ligands from binding to the receptor.
PDGFRA inhibitor
Approval history
- approvedPriority reviewAcceleratedFast trackBreakthroughOct 19, 2016
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOlaratumab ↗
- NCATSTT6HN20MVF ↗
- ChEMBLCHEMBL1743049 ↗
Also known as
- imc3g3
- imc-3g3
- imc-3g3
- imc-3g3
- lartruvo
- lartruvo
- lartruvo
- olaratumab
- olaratumab
- olaratumab
- olaratumab
- olaratumab
- olaratumab
- olaratumab
- olaratumab
- olaratumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03802071 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2019 | Yonsei University |
| NCT03698227 | Phase 2 | Nov 12, 2018 | J. W. Goethe University |
| NCT03437070 | Phase 1 | Oct 31, 2018 | Janssen Pharmaceutica NV, University of Miami |
| NCT03985722 | Phase 1 | Sep 21, 2018 | Grupo Espanol de Investigacion en Sarcomas, Virgen del Rocío University Hospital, Seville |
| NCT03283696 | Phase 1 | Oct 19, 2017 | Eli Lilly |
| NCT03126591 | Phase 1 | Jun 27, 2017 | Eli Lilly, Merck |
| NCT03086369 | Phase 1/Phase 2 (Phase 2) | Jun 22, 2017 | Eli Lilly |
| NCT02783599 | Phase 1 | Oct 1, 2016 | Eli Lilly |
| NCT02677116 | Phase 1 | Aug 1, 2016 | Eli Lilly |
| NCT02659020 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2016 | Eli Lilly |
| NCT02584309 | Phase 2 | Feb 22, 2016 | Washington University in St. Louis |
| NCT02451943 | Phase 3 | Sep 1, 2015 | Eli Lilly |
| NCT02377752 | Phase 1 | Mar 23, 2015 | Eli Lilly |
| NCT02326025 | Phase 1 | Jan 1, 2015 | Eli Lilly |
| NCT01316263 | Phase 2 | Aug 1, 2011 | Eli Lilly |
| NCT01185964 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2010 | Eli Lilly |
| NCT01204710 | Phase 2 | Oct 1, 2010 | Eli Lilly |
| NCT01199822 | Phase 1 | Sep 1, 2010 | Eli Lilly |
| NCT00895180 | Phase 2 | Jul 1, 2010 | Imclone, Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00918203 | Phase 2 | Jan 1, 2010 | Eli Lilly |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 16 | 16 | 4 | 2009 |
| Imclone | For profit | 2 | 1 | 2 | 2006 |
| Grupo Espanol de Investigacion en Sarcomas | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2018 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| J. W. Goethe University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2010 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Virgen del Rocío University Hospital, Seville | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2019 |
12 organizations
Page 1 / 1